Center for Gerontology and Healthcare Research, Brown University School of Public Health, Providence, RI, United States.
Department of Health Services, Policy, and Practice, Brown University School of Public Health, Providence, RI, United States.
Front Public Health. 2023 Aug 10;11:1243958. doi: 10.3389/fpubh.2023.1243958. eCollection 2023.
COVID-19 booster vaccines are highly effective at reducing severe illness and death from COVID-19. Research is needed to identify whether racial and ethnic disparities observed for the primary series of the COVID-19 vaccines persist for booster vaccinations and how those disparities may vary by other characteristics. We aimed to measure racial and ethnic differences in booster vaccine receipt among U.S. Medicare beneficiaries and characterize potential variation by demographic characteristics.
We conducted a cohort study using CVS Health and Walgreens pharmacy data linked to Medicare claims. We included community-dwelling Medicare beneficiaries aged ≥66 years who received two mRNA vaccine doses (BNT162b2 and mRNA-1273) as of 8/1/2021. We followed beneficiaries from 8/1/2021 until booster vaccine receipt, death, Medicare disenrollment, or end of follow-up (12/31/2021). Adjusted Poisson regression was used to estimate rate ratios (RRs) and 95% confidence intervals (CIs) comparing vaccine uptake between groups.
We identified 11,339,103 eligible beneficiaries (mean age 76 years, 60% female, 78% White). Overall, 67% received a booster vaccine (White = 68.5%; Asian = 67.0%; Black = 57.0%; Hispanic = 53.3%). Compared to White individuals, Black (RR = 0.78 [95%CI = 0.78-0.78]) and Hispanic individuals (RR = 0.72 [95% = CI 0.72-0.72]) had lower rates of booster vaccination. Disparities varied by geographic region, urbanicity, and Medicare plan/Medicaid eligibility. The relative magnitude of disparities was lesser in areas where vaccine uptake was lower in White individuals.
Racial and ethnic disparities in COVID-19 vaccination have persisted for booster vaccines. These findings highlight that interventions to improve vaccine uptake should be designed at the intersection of race and ethnicity and geographic location.
COVID-19 加强疫苗在降低 COVID-19 重症和死亡方面非常有效。需要研究是否观察到 COVID-19 疫苗初级系列中存在的种族和民族差异在加强疫苗接种中持续存在,以及这些差异可能如何因其他特征而变化。我们旨在衡量美国医疗保险受益人的加强疫苗接种率中的种族和民族差异,并描述人口特征方面的潜在差异。
我们使用 CVS 健康和沃尔格林药房数据进行了一项队列研究,并与医疗保险索赔数据相关联。我们纳入了截至 2021 年 8 月 1 日年龄在 66 岁及以上、接受过两剂 mRNA 疫苗(BNT162b2 和 mRNA-1273)的居住在社区的医疗保险受益人。我们从 2021 年 8 月 1 日开始随访受益人,直到他们接种加强疫苗、死亡、退出医疗保险或随访结束(2021 年 12 月 31 日)。我们使用调整后的泊松回归来估计疫苗接种率之间的比率比(RR)和 95%置信区间(CI)。
我们确定了 11339103 名合格的受益人(平均年龄 76 岁,60%为女性,78%为白人)。总体而言,67%的人接种了加强疫苗(白人=68.5%;亚裔=67.0%;黑人=57.0%;西班牙裔=53.3%)。与白人相比,黑人(RR=0.78[95%CI=0.78-0.78])和西班牙裔(RR=0.72[95%CI=0.72-0.72])接种加强疫苗的比率较低。差异因地理位置、城市人口密度和医疗保险计划/医疗补助资格而异。在白人疫苗接种率较低的地区,差异的相对幅度较小。
COVID-19 疫苗接种中的种族和民族差异在加强疫苗接种中持续存在。这些发现强调,为提高疫苗接种率而采取的干预措施应在种族和族裔以及地理位置的交叉点上设计。